Announcements Trials
Browse Landscape

Phase

Phase 1 5

Status

Completed 5

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 5Other solid neoplasm 2Thoracic 1Sarcoma 1Gynecologic 1

Conditions

Neoplasms 5

Interventions

pembrolizumab 62Paclitaxel 51Gemcitabine 50Carboplatin 45Docetaxel 43Cisplatin 31Pemetrexed 30Nivolumab 28Bevacizumab 28atezolizumab 22Fluorouracil 22Cetuximab 21Capecitabine 21Irinotecan 20Leucovorin 19Afatinib 18Erlotinib Hydrochloride 15trametinib 14Trastuzumab 13Ipilimumab 13130-nm albumin-bound paclitaxel 13regorafenib 11olaparib 11Sorafenib 11Oxaliplatin 11Drug Therapy 11eribulin 10enzalutamide 10Midazolam 10Injections 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × AC 7700 × Tumor-Agnostic × Clear all
NCT01193595 2014-12-03

Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors

Sanofi

Phase 1 Completed
39 enrolled
Tumor-Agnostic

Neoplasms

NCT01095302 2013-10-16

Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel and Cisplatin in Patients With Solid Tumors

Sanofi

Phase 1 Completed
11 enrolled
Tumor-Agnostic

Neoplasms

NCT00719524 2013-03-11

AVE8062 in Combination With Platinum-taxane Doublet in Advanced Solid Tumor

Sanofi

Phase 1 Completed
71 enrolled
Tumor-Agnostic

Neoplasms

NCT01063946 2011-12-21

A Study to Investigate the Disposition of Radio-labeled AVE8062 Compound Administered as a 30-minute IV Infusion to Patients With Advanced Solid Tumor

Sanofi

Phase 1 Completed
3 enrolled
Tumor-Agnostic

Neoplasms

NCT01021150 2011-06-13

Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Cisplatin in Patients With Solid Tumors

Sanofi

Phase 1 Completed
12 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡